Skip to content

Latest News

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension

Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research. Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes. London, UK, 1 July 2021 …

George Medicines appoints Stefan König as Chief Executive Officer

Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for non-communicable diseases. US FDA grants IND authorization to commence Phase III trials with triple combination candidate for the treatment of hypertension. Chief Business Officer, Karl Roberts, appointed to new role of Chief Operating Officer. London, UK, 3 June 2021 – …